Vitamin C in Dermatology

Abstract Vitamin C is a potent antioxidant drug that can be used topically in dermatology to treat and prevent changes associated with photoageing. It can also be used for the treatment of hyperpigmentation. Because it is unstable and difficult to deliver into the dermis in the optimum dosage, research is being directed to find stable[…]

Are Oral Peptide Drugs on the Horizon?

By Randi Hernandez Peptides and proteins generally have low bioavailability when taken by mouth, and this hurdle has generally prevented the oral delivery of many biologic drugs in the past. However, plant cell walls may be ideal transporters to move protein-based drugs through the digestive system without the drugs being exposed to degradation by stomach[…]

Aspirin Often Wrongly Prescribed for Atrial Fibrillation

More than one-third of U.S. patients with the abnormal heartbeat atrial fibrillation who need a blood thinner to prevent strokes aren’t getting one, researchers say. About 40 percent of “a-fib” patients deemed at moderate to severe risk of stroke because of age or other conditions are prescribed aspirin alone rather than recommended blood thinners such[…]

New Cholesterol-Lowering Treatment

In July 2015, the FDA approved alirocumab (Praluent), the first cholesterol-lowering treatment in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. The following month, the FDA approved the second PCSK9 inhibitor, evolocumab (Repatha).   http://www.slideshare.net/VinceNetto/pcsk9-inhibitors-pp This article highlights several key therapeutics areas for Praluent and Repatha that every[…]

FDA Approves Once-Daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) for Type 2 Diabetes

Ridgefield, Conn., and Indianapolis, May 31, 2016 – The U.S. Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults. Jentadueto XR, which is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), is the seventh new treatment[…]